At a Walgreens in San Francisco’s Japantown, pharmacist Margaret On keeps a few boxes of long acting insulin pens on her shelves featuring the iconic California grizzly bear. These aren’t from the usual pharmaceutical giants, but from CalRx, Governor Gavin Newsom’s ambitious attempt to disrupt the drug industry by launching the state’s own line of affordable generics. While the project was designed to provide a lifeline for the uninsured and challenge the dominance of big pharma, early numbers suggest a slow start. Seven months after launch, the state has distributed roughly 120,000 packs of insulin glargine. Although this is a drop in the bucket compared to California’s total demand, it marks an unprecedented move by a single state to compete directly with global powerhouses like Eli Lilly and Novo Nordisk.
The strategy behind CalRx is as much about politics as it is about public health. With an eye toward a potential 2028 presidential bid, Newsom is positioning healthcare affordability as a cornerstone of his national profile. By partnering with Civica, a Utah based nonprofit manufacturer, California hopes to flood the market with low cost biosimilars to force prices down across the board. Beyond insulin, the state is expanding into free naloxone sprays and planning future releases of budget friendly epinephrine injectors and tuberculosis treatments. Before leaving office in January, Newsom even expressed interest in introducing generic versions of popular weight loss drugs like Ozempic to ease the financial burden on employers and patients alike.
Despite these goals, critics argue that the current impact remains largely symbolic. Geoffrey Joyce, a health policy director at USC’s Schaeffer Center, suggests that while there is some value in providing options for a small fraction of the population, a statewide label cannot solve systemic national failures alone. He notes that truly tackling high drug costs requires a coordinated national effort focused on supply chain vulnerabilities rather than isolated regional experiments. This puts Newsom’s approach at odds with other efforts to lower costs, including Donald Trump’s TrumpRx initiative, which functions more as a coupon directory than a manufacturing operation.
For millions of Californians living with diabetes, however, any reduction in price is welcome news. While many insured patients utilize complex discount programs provided by manufacturers to cap their monthly costs at thirty five dollars, navigating those systems can be daunting and restrictive. Newsom contends that these corporate discounts are merely distractions meant to hide artificially inflated list prices that drive up overall healthcare spending. By creating its own supply line, California is attempting to strip away those layers of bureaucracy and prove that essential medicine can be treated as a public utility rather than a luxury commodity.
